Straits Times Index
3,367.90 +29.33 (+0.88%) S&P 500
5,474.49 -0.60 (-0.01%) Dow
39,158.48 -11.04 (-0.03%) Nasdaq
17,893.63 +14.33 (+0.08%) Bitcoin USD
62,594.10 -63.82 (-0.10%) CMC Crypto 200
1,345.03 +0.52 (+0.04%)
REGN Jul 2024 950.000 call
| Previous close | 101.05 |
| Open | N/A |
| Bid | 93.80 |
| Ask | 103.00 |
| Strike | 950.00 |
| Expiry date | 2024-07-19 |
| Day's range | 101.05 - 101.05 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
Simply Wall St.Insiders At Regeneron Pharmaceuticals Sold US$26m In Stock, Alluding To Potential Weakness
The fact that multiple Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) insiders offloaded a considerable amount of...
ZacksRegeneron (REGN) Gets Positive CHMP Opinion for Lymphoma Drug
Regeneron (REGN) gets positive CHMP recommendation for odronextamab for the treatment of adults with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma.
BenzingaWhat's Going On With Regeneron Pharmaceuticals Stock On Friday?
On Friday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending conditional approval of odronextamab for relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy. Relapsed/refractory (R/R) follicular lymphoma (FL) refers to cases where FL comes back after initial treatment (relapsed) or
